Good MorningEquities rebounded on Wednesday despite another round of bearish news that included the PPI data and earnings from JPMorgan Chase. The PPI data shows producer prices accelerating more than expected to the fastest pace on record. This data is sure to lead to another increase in the CPI data next month or later in the year which brings us to the JPMorgan Chase report. The company says it is bracing for increased economic risks and we think it is a wise decision.
The impacts of Russia's invasion of Ukraine are only beginning to show up in the data and results and those impacts are not good. Rising fuel costs and disruptions to trade are only the tip of the iceberg and threaten to throw the global economy into a recession. The next hurdle for the market will come today with an earnings report from at least half a dozen of the world's largest financial institutions. If they report more of what JPMorgan Chase reported the market sell-off could resume with increased vigor. Featured: Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom (Ad) 
|
Markets | | |
These stocks combine solid fundamentals with a stock price near its 52-week low
Some of you with children may participate in an Easter Egg hunt this weekend. If that’s the case for you, I hope your kids come home with lots of little treasures.
That got me thinking. With t... Read the Full Story |
|
From Our Partners | | Discover the 10 Best AI Stocks to Buy Now!
The AI revolution is reshaping the investment landscape, and knowing where to place your bets is crucial. Our free report reveals the 10 top AI stocks that should be on your radar right now. Don't miss your chance to get in on these high-potential tech plays. | | Download your free report today. |
|
Markets | | | Asian shares fell in muted trading as markets were closed for Good Friday and other holidays.
Benchmarks declined in Tokyo, Seoul and Shanghai. Sydney, Manila, Bangkok and Hong Kong were among markets observing holidays on Friday. U.S. and European markets also were closed.
... Read the Full Story |
|
Markets | | | Stocks closed lower on Wall Street Thursday as investors gave mixed reviews to earnings from four of the nation’s largest banks.
The S&P 500 fell 1.2%, ending a shortened trading week with a 2.1% decline. The Dow Jones Industrial Average fell 0.3% and the Nasdaq composite lost 2.1... Read the Full Story |
|
From Our Partners | | Tesla's About to Prove Everyone Wrong... Again
Back in 2018, when Jeff Brown told everyone to buy Tesla…
The "experts" said Elon was finished and Tesla was headed for bankruptcy.
Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. | | Click here to see why Tesla's about to prove everyone wrong... again. |
|
Tech | | |
These 3 S&P Stocks Could Be Bargains
One of the most common pieces of advice when it comes to investing is to “buy low and sell high”. While this definitely sounds good on paper, finding the right opportunities in the market at the right time is easier said than done. That’s... Read the Full Story |
|
Markets | | |
Solar tracking systems provider Array Technologies (NASDAQ: ARRY) stock has fallen below its pandemic lows despite improving business. The Company manufactures and supplies single-axis solar tracking systems that enable the optimal positioning of a solar array to increase clean and renewable energ... Read the Full Story |
|
From Our Partners | | 2025 is off to a turbulent start—markets are swinging wildly, inflation pressures remain high, and recession fears are creeping back into headlines.
But even in uncertain times, innovation doesn’t slow down.
In fact, artificial intelligence (AI) is accelerating faster than ever—creating new profit opportunities while the broader market struggles.
Our latest research reveals two AI stocks trading under $15 that could thrive even as volatility grows. These under-the-radar companies are positioned to ride the next wave of AI-driven demand—and they’re still flying below most investors’ radar. | | 👉[Click here to access your FREE AI stocks report now.] |
|
Markets | | | Newspaper publisher Lee Enterprises is facing renewed pressure from a hedge fund to speed up its transition to digital publishing and consider adding new digital-savvy leaders to its board after successfully fighting off a hostile takeover from a different hedge fund.
Lee’s largest sh... Read the Full Story |
|
Markets | | |
Robotic process automation (RPA) platform provider UiPath (NASDAQ: PATH) stock has been getting crushed to new lows ever since hitting highs of $90 nearly a year ago. The Company is a leader in RPA, which enables companies to better automate their repetitive processes. It’s both software rob... Read the Full Story |
|
Politics | | | MOSCOW — Russia’s Defense Ministry on Friday promised to ramp up “the scale of missile attacks” on Kyiv in response to Ukraine’s “diversions on the Russian territory.”
The statement comes a day after Russian authorities accused Ukrainian forces of launching airstrikes on residential ... Read the Full Story |
|
Markets | | | A major fertilizer company says the limits Union Pacific is putting on rail traffic to clear up congestion will delay shipments that farmers need during the spring planting season.
CF Industries said Thursday that the railroad ordered it to cut its shipments nearly 20%. Union Pacific ... Read the Full Story |
|
Markets | | | Lululemon Athletica (NASDAQ: LULU) impressed the market when it reported fiscal Q4 earnings at the end of March. The company beat on the bottom line and raised its guidance as demand and pricing combined to boost the earnings results. Read the Full Story |
|
Friday's Early Bird Stock Of The Day Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. | | View Today's Stock Pick |
|
